Policy & Regulation
Bausch + Lomb announces positive new National Eye Institute Data regarding AREDS2 Nutrient Formula for advanced age-related macular degeneration
12 May 2021 -

Bausch + Lomb, a global eye health business of Bausch Health Companies Inc (NYSE/TSX: BHC), announced on Tuesday new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study.

Based on this data, the NEI continues to recommend a specific nutrient formula to help reduce the risk of progression in patients with moderate to advanced Age-Related Macular Degeneration (AMD). That formula is currently found in Bausch + Lomb PreserVision(R) AREDS 2 Formula eye vitamins, which was provided to participants in the last five years of the follow-on study. The study results were presented at the Association for Research in Vision and Ophthalmology annual meeting on 7 May 2021.

'For more than 20 years, Bausch + Lomb has been collaborating with researchers at the NEI to help eye care professionals and the 11 million Americans who are impacted by moderate to advanced AMD,' said Joe Gordon, US president, Bausch + Lomb. 'Since 2001, we have offered a portfolio of eye vitamins based on the most current, available science, and this data further supports the current formulation in our PreserVision(R) AREDS 2 Formula eye vitamins.'



Related Headlines